

Stabilization of the Nitric Oxide (NO) Prodrugs and Anticancer Leads, PABA/NO and Double JS-K, through Incorporation into PEG-Protected Nanoparticles

Varun Kumar,[†] Sam Y. Hong,[‡] Anna E. Maciag,[§] Joseph E. Saavedra,[§]
Douglas H. Adamson,^{||} Robert K. Prud'homme,^{*,†} Larry K. Keefer,[‡] and
Harinath Chakrapani^{*,†,⊥}

Department of Chemical Engineering, Princeton University, Princeton, New Jersey 08544,
Chemistry Section, Laboratory of Comparative Carcinogenesis, and Basic Science
Program, SAIC-Frederick, National Cancer Institute at Frederick, Frederick, Maryland
21702, Department of Chemistry and Institute for Material Science, University of
Connecticut, Storrs, Connecticut 06269, and Department of Chemistry, Indian Institute of
Science Education and Research, Pune 411008, India

Received September 26, 2009; Revised Manuscript Received November 25, 2009; Accepted
December 1, 2009

Abstract: We report the stabilization of the nitric oxide (NO) prodrugs and anticancer lead compounds, PABA/NO (*O*²-[2,4-dinitro-5-[4-(*N*-methylamino)benzoyloxy]phenyl] 1-(*N,N*-dimethylamino)diazene-1-ium-1,2-diolate) and "Double JS-K" 1,5-bis-[1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diol-2-ato]-2,4-dinitrobenzene, through their incorporation into polymer-protected nanoparticles. The prodrugs were formulated in block copolymer-stabilized nanoparticles with sizes from 220 to 450 nm by a novel rapid precipitation process. The block copolymers, with polyethylene glycol (PEG) soluble blocks, provide a steric barrier against NO prodrug activation by glutathione. Too rapid activation and NO release has been a major barrier to effective administration of this class of compounds. The nanoparticle stabilized PABA/NO are protected from attack by glutathione as evidenced by a significant increase in time taken for 50% decomposition from 15 min (unformulated) to 5 h (formulated); in the case of Double JS-K, the 50% decomposition time was extended from 4.5 min (unformulated) to 40 min (formulated). The more hydrophobic PABA/NO produced more stable nanoparticles and correspondingly more extended release times in comparison with Double JS-K. The hydrophobic blocks of the polymer were either polystyrene or polylactide. Both blocks produced nanoparticles of approximately the same size and release kinetics. This combination of PEG-protected nanoparticles with sizes appropriate for cancer targeting by enhanced permeation and retention (EPR) and delayed release of NO may afford enhanced therapeutic benefit.

Keywords: Nitric oxide; PABA/NO; glutathione; glutathione *S*-transferase; nanoparticles; formulation

Introduction

Nitric oxide (NO) is a mediator of diverse physiological processes and has been shown to have antiproliferative

activity.^{1–3} Due to the poor bioavailability of NO, typically prodrugs of nitric oxide such as diazeniumdiolates are used as surrogates of NO.⁴ *O*²-(2,4-Dinitrophenyl) diazeniumdiolates are important members of the diazeniumdiolate class

* Corresponding authors. Mailing address (H.C.): Indian Institute of Science Education and Research, Sai Trinity Building, Garware Circle Pashan Pune 411 021 Maharashtra India. Tel (H.C.): +91-20-2590-8090. E-mail: prudhomm@princeton.edu; harinath@iiserpune.ac.in.

[†] Princeton University.

[‡] Chemistry Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick.

[§] Basic Science Program, SAIC-Frederick, National Cancer Institute at Frederick.

^{||} University of Connecticut.

[⊥] Indian Institute of Science Education and Research.

(1) Furchgott, R. F. Endothelium-Derived Relaxing Factor: Discovery, Early Studies, and Identification as Nitric Oxide (Nobel Lecture). *Angew. Chem., Int. Ed.* **1999**, 38, 1870–1880.

(2) Ignarro, L. J. Nitric Oxide: A Unique Endogenous Signaling Molecule in Vascular Biology (Nobel Lecture). *Angew. Chem., Int. Ed.* **1999**, 38, 1882–1892.

(3) Murad, F. Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signaling (Nobel Lecture). *Angew. Chem., Int. Ed.* **1999**, 38, 1856–1868.

of nitric oxide prodrugs that have shown promising anticancer activity.⁵ Some important examples are JS-K (O²-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate)^{6–15} and PABA/NO,^{16–22} which have both shown potent tumoricidal effects in animal models (Figure 1). For example, JS-K was found to inhibit the in vivo growth of xenografts of cells derived from human leukemia, multiple myeloma, and prostate carcinoma. PABA/NO showed tumoricidal activity against A2780 human ovarian cancer




Figure 1. Chemical structures of the diazeniumdiolate nitric oxide prodrugs used in this study.


- (4) Keefer, L. K. Nitric Oxide (NO)- and Nitroxyl (HNO)-generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities. *Curr. Top. Med. Chem.* **2005**, *5*, 625–636.
- (5) Maciag, A.; Saavedra, J.; Chakrapani, H. The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents. *Anticancer Agents Med. Chem.* **2009**, *9*, 798–803.
- (6) Kitagaki, J.; Yang, Y.; Saavedra, J. E.; Colburn, N.; Keefer, L. K.; Perantoni, A. O. Nitric Oxide Prodrug JS-K Inhibits Ubiquitin E1 and Kills Tumor Cells Retaining Wild-type p53. *Oncogene* **2009**, *28*, 619–624.
- (7) Simeone, A.-M.; McMurtry, V.; Nieves-Alicea, R.; Saavedra, J.; Keefer, L.; Johnson, M.; Tari, A. TIMP-2 Mediates the Anti-invasive Effects of the Nitric Oxide-releasing Prodrug JS-K in Breast Cancer Cells. *Breast Cancer Res.* **2008**, *10*, R44.
- (8) Chakrapani, H.; Kalathur, R. C.; Maciag, A. E.; Citro, M. L.; Ji, X.; Keefer, L. K.; Saavedra, J. E. Synthesis, Mechanistic Studies, and Anti-proliferative Activity of Glutathione/glutathione S-transferase-activated Nitric Oxide Prodrugs. *Bioorg. Med. Chem.* **2008**, *16*, 9764–9771.
- (9) Chakrapani, H.; Goodblatt, M. M.; Udupi, V.; Malaviya, S.; Shami, P. J.; Keefer, L. K.; Saavedra, J. E. Synthesis and in vitro Anti-leukemic Activity of Structural Analogues of JS-K, an Anti-cancer Lead Compound. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 950–953.
- (10) Kiziltepe, T.; Hideshima, T.; Ishitsuka, K.; Ocio, E. M.; Raje, N.; Catley, L.; Li, C.-Q.; Trudel, L. J.; Yasui, H.; Vallet, S.; Kutok, J. L.; Chauhan, D.; Mitsiades, C. S.; Saavedra, J. E.; Wogan, G. N.; Keefer, L. K.; Shami, P. J.; Anderson, K. C. JS-K, a GST-activated Nitric Oxide Generator, Induces DNA Double-strand Breaks, Activates DNA Damage Response Pathways, and Induces Apoptosis in vitro and in vivo in Human Multiple Myeloma Cells. *Blood* **2007**, *110*, 709–718.
- (11) Udupi, V.; Yu, M.; Malaviya, S.; Saavedra, J. E.; Shami, P. J. JS-K, A Nitric Oxide Prodrug, Induces Cytochrome c Release and Caspase Activation in HL-60 Myeloid Leukemia Cells. *Leuk. Res.* **2006**, *30*, 1279–1283.
- (12) Shami, P. J.; Saavedra, J. E.; Bonifant, C. L.; Chu, J.; Udupi, V.; Malaviya, S.; Carr, B. I.; Kar, S.; Wang, M.; Jia, L.; Ji, X.; Keefer, L. K. Antitumor Activity of JS-K [O²-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate] and Related O²-Aryl Diazeniumdiolates in Vitro and in Vivo. *J. Med. Chem.* **2006**, *49*, 4356–4366.
- (13) Liu, J.; Li, C.; Qu, W.; Leslie, E.; Bonifant, C. L.; Buzard, G. S.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. Nitric Oxide Prodrugs and Metallochemotherapeutics: JS-K and CB-3-100 Enhance Arsenic and Cisplatin Cytotoxicity by Increasing Cellular Accumulation. *Mol. Cancer Ther.* **2004**, *3*, 709–714.
- (14) Shami, P. J.; Saavedra, J. E.; Wang, L. Y.; Bonifant, C. L.; Diwan, B. A.; Singh, S. V.; Gu, Y.; Fox, S. D.; Buzard, G. S.; Citro, M. L.; Waterhouse, D. J.; Davies, K. M.; Ji, X.; Keefer, L. K. JS-K, a Glutathione/Glutathione S-Transferase-activated Nitric Oxide Donor of the Diazeniumdiolate Class with Potent Antineoplastic Activity. *Mol. Cancer Ther.* **2003**, *2*, 409–417.

xenografts in female SCID mice with a potency comparable to that of cisplatin.

The general mechanism of activation of such prodrugs involves a nucleophilic aromatic substitution by glutathione (GSH) followed by spontaneous decomposition of the ensuing diazeniumdiolate anion to generate nitric oxide under physiological conditions (Scheme 1).⁵ The aforementioned reaction was found to be catalyzed by glutathione S-transferase (GST), a class of detoxification enzymes that is frequently overexpressed in cancers.^{14,21}

Double JS-K¹² (Figure 1) is a second-generation JS-K analogue that was designed to generate up to 4 mol of NO

- (15) Ren, Z.; Kar, S.; Wang, Z.; Wang, M.; Saavedra, J. E.; Carr, B. I. JS-K, A Novel Non-ionic Diazeniumdiolate Derivative, Inhibits Hep 3B Hepatoma Cell Growth and Induces c-Jun Phosphorylation via Multiple MAP Kinase Pathways. *J. Cell. Physiol.* **2003**, *197*, 426–434.
- (16) Townsend, D. M.; Manevich, Y.; He, L.; Hutchens, S.; Pazoles, C. J.; Tew, K. D. Novel Role for Glutathione S-Transferase {pi}: Regulator of Protein S-Glutathionylation Following Oxidative And Nitrosative Stress. *J. Biol. Chem.* **2009**, *284*, 436–445.
- (17) Andrei, D.; Maciag, A.; Chakrapani, H.; Citro, M. L.; Keefer, L. K.; Saavedra, J. E. Aryl Bis(diazeniumdiolates): Potent Inducers of S-Glutathionylation of Cellular Proteins and Their in Vitro Antiproliferative Activities. *J. Med. Chem.* **2008**, *51*, 7944–7952.
- (18) Townsend, D. M.; Findlay, V. J.; Fazilev, F.; Ogle, M.; Fraser, J.; Saavedra, J. E.; Ji, X.; Keefer, L. K.; Tew, K. D. A Glutathione S-Transferase {pi}-Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins. *Mol. Pharmacol.* **2006**, *69*, 501–508.
- (19) Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X.; Keefer, L. K. PABA/NO as an Anticancer Lead: Analogue Synthesis, Structure Revision, Solution Chemistry, Reactivity toward Glutathione, and in Vitro Activity. *J. Med. Chem.* **2006**, *49*, 1157–1164.
- (20) Findlay, V. J.; Townsend, D. M.; Morris, T. E.; Fraser, J. P.; He, L.; Tew, K. D. A Novel Role for Human Sulfiredoxin in the Reversal of Glutathionylation. *Cancer Res.* **2006**, *66*, 6800–6806.
- (21) Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X.; Tew, K. D. Tumor Cell Responses to a Novel Glutathione S-Transferase-Activated Nitric Oxide-Releasing Prodrug. *Mol. Pharmacol.* **2004**, *65*, 1070–1079.
- (22) Chakrapani, H.; Wilde, T. C.; Citro, M. L.; Goodblatt, M. M.; Keefer, L. K.; Saavedra, J. E. Synthesis, Nitric Oxide Release, and Anti-leukemic Activity of Glutathione-activated Nitric Oxide Prodrugs: Structural Analogues of PABA/NO, an Anti-cancer Lead Compound. *Bioorg. Med. Chem.* **2008**, *16*, 2657–2664.

Scheme 1. Glutathione-Activated Nitric Oxide Release from NO Prodrug

per mole of compound and has shown potent in vitro antiproliferative effects against human leukemia cells.¹⁷

As JS-K and PABA/NO react with glutathione even in the absence of GST, our goal during preclinical development of such prodrugs was to minimize reactivity of the prodrug with glutathione in order to increase circulation time and ultimately its efficacy. Our approach toward stabilizing nitric oxide prodrugs was to encapsulate these prodrugs in the form of suitable nanoparticles.

Nanoparticles (NP) have previously been reported as potential delivery vehicles for various therapeutic agents.^{23–25} Gref et al.²⁵ reported the advantages of PEGylated polymeric nanoparticles in terms of the circulation time and release of the encapsulated drug. Polyethylene glycol-*b*-poly(lactic-co-glycolic acid) (PEG-*b*-PLGA)-based nanospheres showed longer circulation time and reduced liver uptake compared to PLGA nanospheres with no PEG coating.²⁵ The concept of a protected prodrug has been widely used to sustain release of cytotoxic agents. Schoenmakers et al. have tailored the cleavage kinetics of ester bonds to control paclitaxel release.²⁶ The research groups of Baker²⁷ and Kannan^{28,29} have prepared prodrugs based on dendrimer scaffolds. Sengupta et al.³⁰ conjugated doxorubicin with PLGA and nucleated the prodrug inside a nanoscale PEGylated phospholipid envelope. The conjugation led to a shift in concentration (~1.8 times) corresponding to half-maximal response. Ansell

et al.³¹ conjugated paclitaxel with various lipophilic alcohols to tune the hydrophobicity of the drug and hence its partitioning rate, which directly correlated to efficacy.

In this study, nitric oxide prodrug molecules have been encapsulated into the nanoparticle form and the impact of the polymer protecting layer has been analyzed. The formation and processing of the nanoparticles were observed not to affect the molecular activity of the drug compounds. The formulated nanoparticles of the drug compounds showed significant improvement in stability against glutathione, and an antiproliferative activity similar to that of the naked drug molecules.

Experimental Section

Materials. The nitric oxide prodrugs JS-K, PABA/NO, and Double JS-K were prepared using previously reported methods.^{12,19,32} Poloxamer 188 was obtained from BASF Corporation, Parsippany, NJ. Trehalose (D-trehalose dihydrate) was purchased from Sigma-Aldrich Inc., Milwaukee, WI. The stabilizer, poly-L-lactide-*b*-poly(ethylene glycol) (PLA-*b*-PEG, 4.2k-*b*-5k) was purchased from Polymer Source, Inc., Richmond, IN. Polystyrene-*b*-poly(ethylene glycol) (PS-*b*-PEG, 1.5k-*b*-3k) was synthesized by high vacuum anionic polymerization methods³³ using hydroxide capped PS initiated by potassium naphthalenide followed by addition of ethylene oxide.

Nanoparticle Formation. Aqueous Solution. Poloxamer 188 and trehalose were dissolved in Milli-Q water at the concentration of 9.5 and 12 mg/mL respectively. The aqueous solution was filtered through 0.2 μ m syringe filter (Whatman Inc., Florham park, NJ).

Organic Solution. Block copolymer (PS-*b*-PEG or PLA-*b*-PEG) was dissolved in 3.5 mL of tetrahydrofuran (THF), at the concentration of 8.6 mg/mL. The mixture was sonicated to give a clear solution. NO prodrug (~10.5 mg) was then added to the clear solution. The mixed solution was sonicated and filtered through a 0.2 μ m syringe filter.

Particle Formation. The nanoparticles were produced by a rapid micromixing, rapid precipitation, and block copolymer-directed encapsulation process called Flash NanoPrecipitation

- (23) Allen, C.; Maysinger, D.; Eisenberg, A. Nano-engineering Block Copolymer Aggregates for Drug Delivery. *Colloids Surf., B* **1999**, *16*, 3–27.
- (24) Kumar, V.; Prud'homme, R. K. Thermodynamic Limits on Drug Loading in Nanoparticle Cores. *J. Pharm. Sci.* **2008**, *97*, 4904–4914.
- (25) Gref, R.; Minamitake, Y.; Peracchia, M.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable Long-circulating Polymeric Nanospheres. *Science* **1994**, *263*, 1600–1603.
- (26) Schoenmakers, R. G.; Wetering, P. v. d.; Elbert, D. L.; Hubbell, J. A. The Effect of the Linker on the Hydrolysis Rate of Drug-linked Ester Bonds. *J. Controlled Release* **2004**, *95*, 291–300.
- (27) Patri, A. K.; Kukowska-Latallo, J. F.; Baker, J. R. Targeted Drug Delivery with Dendrimers: Comparison of the Release Kinetics of Covalently Conjugated Drug and Non-covalent Drug Inclusion Complex. *Adv. Drug Delivery Rev.* **2005**, *57*, 2203–2214.
- (28) Kurtoglu, Y. E.; Navath, R. S.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R. M. Poly(amidoamine) Dendrimer-drug Conjugates with Disulfide Linkages for Intracellular Drug Delivery. *Biomaterials* **2009**, *30*, 2112–2121.
- (29) Perumal, O.; Khandare, J.; Kolhe, P.; Kannan, S.; Lieh-Lai, M.; Kannan, R. M. Effects of Branching Architecture and Linker on the Activity of Hyperbranched Polymer-Drug Conjugates. *Bioconjugate Chem.* **2009**, *20*, 842–846.

- (30) Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal Targeting of Tumour Cells and Neovasculature with a Nanoscale Delivery System. *Nature* **2005**, *436*, 568–572.
- (31) Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prud'homme, R. K.; Mayer, L. D. Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates. *J. Med. Chem.* **2008**, *51*, 3288–3296.
- (32) Saavedra, J. E.; Srinivasan, A.; Bonifant, C. L.; Chu, J.; Shanklin, A. P.; Flippen-Anderson, J. L.; Rice, W. G.; Turpin, J. A.; Davies, K. M.; Keefer, L. K. The secondary amine/nitric oxide complex ion $R_2N[N(O)NO]^-$ as nucleophile and leaving group in S_NAr reactions. *J. Org. Chem.* **2001**, *66*, 3090–3098.
- (33) Hillmyer, M. A.; Bates, F. S. Synthesis and Characterization of Model Polyalkane-Poly(ethylene oxide) Block Copolymers. *Macromolecules* **1996**, *29*, 6994–7002.




Figure 2. Schematic of nanoparticle formulation. Organic solvent stream, THF, is mixed with nonsolvent, water, in a MIVM to precipitate the NO prodrug followed by stabilization with the block copolymers.

(FNP), which is shown schematically in Figure 2. The design and operation of the multi-inlet vortex mixer (MIVM) used to formulate the nanoparticles have been described previously.^{34–38} The organic stream (12 mL/min) was mixed against the aqueous streams (3 streams, each at 40 mL/min) in the MIVM to precipitate the drug followed by stabilization with the block copolymers. The nanoparticle suspension was collected in a 50 mL sterile tube (Becton Dickinson & Co., Franklin Lakes, NJ).

Dynamic laser light scattering was used to determine the particle size (expressed as the intensity weighted diameter) with a Zeta sizer (Malvern Instruments, Inc., Westborough, MA). All measurements were made at 532 nm wavelength at the scattering angle of 173° using normal resolution mode as the analysis model.

Processing of Nanoparticle Dispersion. The nanoparticle dispersion was processed using two different routes, dialysis and lyophilization, to remove the residual organic solvent.

Dialysis. The nanoparticle dispersion was dialyzed against pure water using a Spectra/Por dialysis membrane (Spectrum Laboratories, Inc., CA) with a molecular weight cut-off (MWCO) of 6–8 kDa.

Lyophilization. The undialyzed nanoparticle suspension was immediately transferred into a series of 2 mL sterile cryogenic vials (Corning Inc., Corning, NY) dipped into a dry ice/acetone bath to rapidly freeze the sample. The vials were left in the bath for 30–40 min. The vials were lyophilized at –76 °C and 70 mTorr for 3 days. The

lyophilized powder was reconstituted in PBS (pH = 7.4) to the desired concentration. 2 mL of PBS was added to each cryogenic vial containing the lyophilized powder, and the solution was sonicated with probe tip sonication for ~3 min at 2–3 W (Fisher Scientific model 100 sonic dismembrator, with a 3.2 mm tip) with the vial dipped in an ice bath to avoid heating during sonication.

Stability Studies. A glutathione stock solution (40 mM) was prepared in 0.1 M phosphate buffer (pH = 7.4). A DMSO stock solution of the prodrug (1 mM) was prepared. To 800 µL of 0.1 M phosphate buffer (pH = 7.4) were added 100 µL of glutathione (40 mM) and 100 µL of prodrug (1 mM), and the disappearance of the prodrug was monitored using an Agilent 1100 series HPLC fitted with a C-18 reverse phase column (Phenomenex Luna 250 × 4.60 mm) operating at 300 nm and run isocratically with acetonitrile:water (75:25). The studies with the nanoparticles were conducted as described above except that the reconstituted nanoparticles were used instead of the DMSO stock solution of the prodrug.

Cell Culture and Cytotoxicity Assays. Human leukemia U937 and human lung cancer H1703 cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in RPMI 1640 medium (Gibco, Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (Gemini Bio-Products, Sacramento, CA), 100 U/mL penicillin and 2 mM glutamine, at 37 °C and 5% CO₂. The CellTiter 96 nonradioactive cell proliferation assay (MTT assay, Promega, Madison, WI), performed according to the manufacturer's protocol, was used to measure cell growth. Cells were seeded in 96-well plates at the density of 10⁴ per well and allowed to grow for 24 h before addition of the drugs. Diazeniumdiolate prodrugs were prepared as 10 mM stock solution in DMSO (Sigma, St. Louis, MO). Increasing drug concentrations in 10 µL of PBS were added to 100 µL of the culture medium for 72 h. Each compound concentration was represented in six repeats, and the screening was performed as at least two independent experiments. IC₅₀ values were determined using curve fitting algorithm by SigmaPlot (Systat, San Jose, CA).

Results

PABA/NO Nanoparticles. Nanoparticles of 240 and 225 nm diameter were obtained for PS-*b*-PEG- and PLA-*b*-PEG-

- (34) Gindy, M. E.; Ji, S.; Hoyer, T. R.; Panagiotopoulos, A. Z.; Prud'homme, R. K. Preparation of Poly(ethylene glycol) Protected Nanoparticles with Variable Bioconjugate Ligand Density. *Biomacromolecules* **2008**, *9*, 2705–2711.
- (35) Gindy, M. E.; Panagiotopoulos, A. Z.; Prud'homme, R. K. Composite Block Copolymer Stabilized Nanoparticles: Simultaneous Encapsulation of Organic Actives and Inorganic Nanostructures. *Langmuir* **2008**, *24*, 83–90.
- (36) Johnson, B. K.; Prud'homme, R. K. Chemical Processing and Micromixing in Confined Impinging Jets. *AIChE J.* **2003**, *49*, 2264–2282.
- (37) Liu, Y.; Cheng, C.; Liu, Y.; Prud'homme, R. K.; Fox, R. O. Mixing in a Multi-inlet Vortex Mixer (MIVM) for Flash Nanoprecipitation. *Chem. Eng. Sci.* **2008**, *63*, 2829–2842.
- (38) Akbulut, M.; Ginart, P.; Gindy, M. E.; Theriault, C.; Chin, K. H.; Soboyejo, W.; Prud'homme, R. K. Generic Method of Preparing Multifunctional Fluorescent Nanoparticles Using Flash Nanoprecipitation. *Adv. Funct. Mater.* **2009**, *19*, 718–725.




Figure 3. Particle size distributions of undialyzed PABA/NO nanoparticles stabilized by PS-*b*-PEG (240 nm) (▼) and PLA-*b*-PEG (225 nm) (■). The slow ripening of undialyzed nanoparticles stabilized by PS-*b*-PEG shows growth to 440 nm in 20 h (▽).

stabilized particles, respectively (Figure 3). A slow increase in size was observed for the undialyzed dispersion during its storage at 4 °C (Figure 3) so that the average particle size grew to 440 nm over 20 h. The process of diffusion-induced growth of particle size is termed Ostwald ripening and has been modeled quantitatively for these polymer-protected nanoparticles.³⁹ The slow growth resulted in macroscopic precipitation after two to three days. PS-*b*-PEG stabilized PABA/NO nanoparticles were formed with 1× PBS (pH = 7.3) as the aqueous stream. The stability results were qualitatively similar; as 195 nm sized particles at $t = 0$ h grew to 250 nm over 2.5 h and precipitated over 24 h. The particles in DI water grew in size by 65% over the same period but were more stable after 24 h. The process of particle growth by Ostwald ripening is relatively insensitive to ionic strength.

Dialysis of the nanoparticle dispersion resulted in precipitation in the dialysis membrane within a few hours during dialysis. However, freeze-drying of the sample immediately after formation led to a stable powder form that could be reconstituted to the original (initial) particle size at the time of administration. Freeze-drying also removes the THF cosolvent used in processing.

Double JS-K Nanoparticles. Stable nanoparticles of the JS-K drug could not be formed. The product stream from the MIVM immediately precipitated as a macroscopic solid. This lack of protection by the block copolymer during precipitation arises from two effects. First, JS-K was relatively soluble and so the Ostwald ripening kinetics⁴⁰ was rapid and the high surface energy nanoparticles re-form as larger, lower surface




Figure 4. Particle size distributions of undialyzed Double JS-K nanoparticles stabilized by PS-*b*-PEG (200 nm) (▼) and PLA-*b*-PEG (195 nm) (■). The growth of the PS-*b*-PEG stabilized particles (to 290 nm) over 1 h is shown (▽).

area, precipitates. Also, the hydrophobic block of the polymer has a less favorable interaction energy with the more hydrophilic JS-K particle surface. This lack of strong interaction leads to poor coverage and protection by the block copolymer. We have studied this phenomenon in the context of hydrophobic polypeptide nanoparticle formation.⁴¹ In order to increase the hydrophobicity, Double JS-K was synthesized (Figure 1).¹² Nanoparticles formed of Double JS-K with sizes 200 and 195 nm were obtained using PS-*b*-PEG and PLA-*b*-PEG as stabilizers, respectively (Figure 4).

Both dialyzed and undialyzed dispersions gave a macroscopic precipitate within a few hours, displaying a higher instability compared to PABA/NO nanoparticles. Figure 4 shows the initial sizes of the Double JS-K nanoparticles and then the particle size for the PS-*b*-PEG-stabilized nanoparticles where the particle size has grown to 290 nm after 1 h. This observation is consistent with the somewhat lower calculated solid phase partition coefficients (i.e., $\log P$) of Double JS-K, $\log P = 2.12$, and PABA/NO, $\log P = 3.30$.⁴² Immediate freeze-drying of the sample was carried out to prepare stable Double JS-K nanoparticle powders.

Since the relevant assays and applications involve time scales of hours, and the release of drug, which is the driver of Ostwald ripening, is the desired outcome of drug delivery, long-term changes in particle size in vitro are not a significant problem. The dispersion from the mixer, with the shown particle distributions, was immediately frozen and lyophilized. Redispersion at the time of use resulted in particle sizes identical to the initial distribution. The molecular activity/

(39) Liu, Y.; Kathan, K.; Saad, W.; Prud'homme, R. K. Ostwald Ripening of Beta-Carotene Nanoparticles. *Phys. Rev. Lett.* **2007**, *98*, 036102.

(40) Kumar, V.; Wang, L.; Riebe, M.; Tung, H.; Prud'homme, R. K. Formulation and Stability of Itraconazole and Odanacatib Nanoparticles: Governing Physical Parameters. *Mol. Pharmaceutics* **2009**, *6*, 1118–1124.

(41) Chen, T.; D'Addio, S. M.; Kennedy, M. T.; Swietlow, A.; Kevrekidis, I. G.; Panagiotopoulos, A. Z.; Prud'homme, R. K. Protected Peptide Nanoparticles: Experiments and Brownian Dynamics Simulations of the Energetics of Assembly. *Nano Lett.* **2009**, *9*, 2218–2222.

(42) Molinspiration Cheminformatics, Bratislava, Slovak Republic, <http://www.molinspiration.com/services/properties.html>. Accessed on June 20, 2009.




Figure 5. UV-vis absorbance spectra of formulated (stabilized by PS-*b*-PEG) vs unformulated PABA/NO. The spectra (peak position and intensity) confirm that molecular integrity is preserved during nanoparticle formation and lyophilization.

Table 1. Calculated Recovery of PABA/NO and Double JS-K from Their Corresponding Formulations

compounds	expected drug concn (mg/mL) ^a	estimated drug concn (mg/mL) for NP stabilized with ^b	
		PS- <i>b</i> -PEG	PLA- <i>b</i> -PEG
PABA/NO	0.27	0.23	0.22
Double JS-K	0.26	0.24	0.23

^a Expected drug concentration is based on the amount of drug used during the nanoparticle formulation. ^b Estimated drug concentration is the actual drug content based on the HPLC analysis on formulated nanoparticles.

effective concentration of the formulated PABA/NO in lyophilized nanoparticle form was compared to the unformulated PABA/NO using UV-absorbance via a UV-vis spectrophotometer (Evolution 300, Thermo Electron Corporation, England). The PABA/NO displays a characteristic absorbance peak at 321 nm. The lyophilized powder was dissolved in THF to yield $\sim 9.4 \times 10^{-3}$ mg/mL PABA/NO, and the UV absorbance from the solution was compared with the naked PABA/NO drug solution in THF at $\sim 8.56 \times 10^{-3}$ mg/mL. Absorbance peaks at ~ 321 nm of around the same intensity were observed from both the samples (Figure 5).

Next, these nanoparticles were reconstituted in phosphate buffered saline (PBS, pH 7.4). Based on a calibration curve generated by HPLC analysis of PABA/NO standards, the amount of PABA/NO in the formulation was calculated (Table 1). A similar procedure was carried out for Double JS-K nanoparticles and the recovery of Double JS-K was found to be comparable to that of PABA/NO.

Reaction of Formulated and Unformulated Prodrug with Glutathione. The reaction of PABA/NO with 4 mM glutathione was monitored via HPLC analysis. Under pseudo-first-order conditions, a time-dependent disappearance of PABA/NO was observed and a rate constant of $4.6 \times 10^{-2} \text{ s}^{-1}$ was obtained; the calculated half-life was 15 min (Figure 6).




Figure 6. Decomposition of PABA/NO in 4 mM glutathione solution in pH 7.4 phosphate buffer at 25 °C.




Figure 7. Decomposition of Double JS-K in 4 mM glutathione solution in pH 7.4 phosphate buffer at 25 °C.

Under identical reaction conditions, Double JS-K was found to disappear with a half-life of 4.5 min and a pseudo-first-order rate constant of 0.154 s^{-1} (Figure 7).

Next, the nanoparticle formulations of PABA/NO were tested. In the case of the PS-*b*-PEG-stabilized PABA/NO formulation, roughly 50% of the PABA/NO remained after ~ 5 h while for PLA-*b*-PEG-stabilized PABA/NO formulation, roughly 50% remained after ~ 3 h (Figure 8).

Similarly, the formulation was found to protect Double JS-K. The PS-*b*-PEG and PLA-*b*-PEG formulations were similar in behavior: roughly 50% Double JS-K disappeared in 40 min (Figure 9).

Antiproliferative Activity of PABA/NO. The antiproliferative effects of PABA/NO were determined in two cell lines, human leukemia U937 and human non-small cell lung cancer H1703 cells. Nearly identical IC_{50} values for formulated and unformulated PABA/NO were obtained (Table 2). A comparison of inhibitory activity of PABA/NO against U937 cells can be found in Figure 10.




Figure 8. Decomposition of formulated PABA/NO in 4 mM glutathione solution in pH 7.4 phosphate buffer at 25 °C.




Figure 9. Decomposition of formulated Double JS-K in 4 mM glutathione solution in pH 7.4 phosphate buffer at 25 °C.

Table 2. Antiproliferative Activities (IC_{50}) of PABA/NO, PS-*b*-PEG Stabilized PABA/NO and PLA-*b*-PEG Stabilized PABA/NO

cell lines	PABA/NO (μ M)	
	stabilized by PS- <i>b</i> -PEG	stabilized by PLA- <i>b</i> -PEG
U937	6.5	4.4
H1703	8.7	5.3

Discussion

The encapsulation and NO release of JS-K, Double JS-K, and PABA/NO were consistent with their respective calculated hydrophobicities. The calculated solid phase partition coefficients (i.e., $\log P$) of the compounds are JS-K, $\log P = 1.99$; Double JS-K, $\log P = 2.12$; and PABA/NO, $\log P = 3.30$.⁴² Attempts at formulating JS-K into nanoparticle form were unsuccessful due to its relatively higher solubility in aqueous solution. However, the precipitation into nanoparticle form of the more hydrophobic PABA/NO and Double JS-K were successful with both PS-*b*-PEG and PLA-




Figure 10. Antiproliferative activity of PABA/NO, PS-*b*-PEG-stabilized PABA/NO and PLA-*b*-PEG-stabilized PABA/NO.

b-PEG block copolymers. There is little difference in sizes of the nanoparticles produced by either block copolymer, and only a small difference in the release rates of drug from either polymer. The dependence of drug release on the interaction between drug and polymer has been previously studied.⁴³ A slightly better protection of PABA/NO by PS block (solubility parameter, $\delta_{PS} = 18.6 \text{ MPa}^{1/2}$)⁴⁰ compared to PLA block (solubility parameter, $\delta_{PLA} = 23.3 \text{ MPa}^{1/2}$)⁴³ could be due to the stronger interaction between the more hydrophobic PS block and PABA/NO compared to less hydrophobic PLA. However it might also be related to the higher glass transition temperature of PS ($T_g = 95 \text{ °C}$)⁴⁰ providing higher rigidity on the nanoparticle surface compared to PLA ($T_g = 60\text{--}65 \text{ °C}$).⁴⁴ But the biodegradability of the PLA block relative to the PS block is probably the most important criterion for selection of the polymer for eventual therapeutic applications. The stability of the Double JS-K nanoparticles was significantly better than that of JS-K because the Ostwald ripening rate depends both on the solubility of the compound⁴⁰ (Double JSK being more hydrophobic) and also upon the diffusion coefficient.³⁹ Double JS-K, being a larger molecule, is expected to have a diffusion coefficient approximately 40% smaller than JS-K. Therefore, Double JS-K nanoparticles were sufficiently stable that they could be freeze-dried and administered. The increased rate of glutathione-decomposition of Double JS-K relative to PABA/NO is related to the higher solubility of the Double JS-K which favors dissolution.

(43) Liu, J.; Xiao, Y.; Allen, C. Polymer-drug Compatibility: A Guide to the Development of Delivery Systems for the Anticancer Agent, Ellipticine. *J. Pharm. Sci.* **2004**, *93*, 132–143.

(44) Daniels, A. U.; Chang, M. K. O.; Andriano, K. P.; Heller, J. Mechanical Properties of Biodegradable Polymers and Composites Proposed for Internal Fixation of Bone. *J. Appl. Biomater.* **1990**, *1*, 57–78.

Conclusions

Nitric oxide prodrugs with antiproliferative activity can be stabilized as nanoparticles with significant protective effects from activation by glutathione. The protection for times of 5–6 h is believed to be optimal for delivery to solid cancer tumors by the mechanism of enhanced permeation and retention (EPR).^{45–47} By this mechanism particles in the size range of 100–300 nm can pass through the defects in the rapidly growing vasculature in tumors and deposit in the tissue. This requires effective passivation of the nanoparticle to prevent premature removal by the reticuloendothelial system (RES). We have demonstrated that PEG-

protected particles produced by Flash NanoPrecipitation using the block copolymers in this study have circulation times in mice of over 24 h.³¹ The ability to coprecipitate drugs in the same nanoparticle makes it possible to formulate nanoparticle “drug cocktails” where multiple drugs can be released from the same nanoparticle in a dose-controlled and time-controlled manner. Our demonstration of tuned release of paclitaxel from these nanoparticles³¹ makes the combination of it with these NO-releasing compounds an ideal candidate for a dual drug delivery study. The paclitaxel release in our previous study could be tuned to release drug over times from 20 min to 24 h depending on the method of conjugation of the drug. This time scale could be matched to the 5–6 h release of PABA/NO.

- (45) Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumor-tropic Accumulation of Proteins and the Antitumor Agent Smancs. *Cancer Res.* **1986**, *46*, 6387–6392.
- (46) Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. *Adv. Drug Delivery Rev.* **1991**, *6*, 181–202.
- (47) Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. *J. Controlled Release* **2001**, *74*, 47–61.

Acknowledgment. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, as well as by National Cancer Institute Contract HHSN261200800001E and the National Science Foundation under the NIRT grant for Nanoparticle Formation Technologies (CBET 0506966).

MP900245H